Monocarboxylate Transporter 8 Deficiency: From Pathophysiological Understanding to Therapy Development
Genetic defects in the thyroid hormone transporter monocarboxylate transporter 8 (MCT8) result in MCT8 deficiency. This disorder is characterized by a combination of severe intellectual and motor disability, caused by decreased cerebral thyroid hormone signalling, and a chronic thyrotoxic state in p...
Main Authors: | Ferdy S. van Geest, Nilhan Gunhanlar, Stefan Groeneweg, W. Edward Visser |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2021.723750/full |
Similar Items
-
In a zebrafish biomedical model of human Allan-Herndon-Dudley syndrome impaired MTH signaling leads to decreased neural cell diversity
by: Nádia Silva, et al.
Published: (2023-05-01) -
Corrigendum: In a zebrafish biomedical model of human Allan-Herndon-Dudley syndrome impaired MTH signaling leads to decreased neural cell diversity
by: Nádia Silva, et al.
Published: (2023-05-01) -
Monocarboxylate Transporter 8 Deficiency: Delayed or Permanent Hypomyelination?
by: Pieter Vancamp, et al.
Published: (2020-05-01) -
Mathematical modeling and simulation of thyroid homeostasis: Implications for the Allan-Herndon-Dudley syndrome
by: Tobias M. Wolff, et al.
Published: (2022-12-01) -
Diagnosis and Therapy in MCT8 Deficiency: Ongoing Challenges
by: Matthijs E.T. Freund, et al.
Published: (2024-03-01)